Edgewise Therapeutics Stock Price on December 16, 2024
| EWTX Stock | USD 30.78 0.77 2.57% |
If you're considering investing in Edgewise Stock, it is important to understand the factors that can impact its price. As of today, the current price of Edgewise Therapeutics stands at 30.78, as last reported on the 20th of December, with the highest price reaching 32.61 and the lowest price hitting 30.06 during the day. Edgewise Therapeutics appears to be not too volatile, given 3 months investment horizon. Edgewise Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0802, which denotes the company had a 0.0802% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Edgewise Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Edgewise Therapeutics' Downside Deviation of 3.47, coefficient of variation of 769.63, and Mean Deviation of 3.57 to check if our risk estimates are consistent with your expectations.
At this time, Edgewise Therapeutics' Stock Based Compensation is fairly stable compared to the past year. Sale Purchase Of Stock is likely to rise to about 126.5 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 195.7 M in 2024. . At this time, Edgewise Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price To Book Ratio is likely to rise to 2.30 in 2024, whereas Price Earnings Ratio is likely to drop (7.31) in 2024. Edgewise Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Edgewise |
Sharpe Ratio = 0.0802
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EWTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.77 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Edgewise Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edgewise Therapeutics by adding it to a well-diversified portfolio.
Price Book 5.8125 | Book Value 5.178 | Enterprise Value 2.4 B | Enterprise Value Ebitda (2.60) | Shares Float 54.4 M |
Edgewise Therapeutics Main Headline on 16th of December 2024
Edgewise Therapeutics Lead Candidate Reduces Biomarker Level... by finance.yahoo.com
On Monday, Edgewise Therapeutics, Inc., revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy , is a genetic disorder that causes progressive muscle weakness. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thicken
Edgewise Therapeutics Valuation on December 16, 2024
It is possible to determine the worth of Edgewise Therapeutics on a given historical date. On December 16, 2024 Edgewise was worth 28.2 at the beginning of the trading date compared to the closed value of 32.69. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Edgewise Therapeutics stock. Still, in general, we apply an absolute valuation method to find Edgewise Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Edgewise Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Edgewise Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 28.50 | 29.00 | 27.52 | 27.62 | 495,263 | |
12/16/2024 | 28.20 | 35.50 | 28.00 | 32.69 | 3,836,770 |
| 33.37 | 33.38 | 29.97 | 30.17 | 1,641,582 |
| Backtest Edgewise Therapeutics | | | Edgewise Therapeutics History | | | Edgewise Therapeutics Valuation | Previous | Next |
Edgewise Therapeutics Trading Date Momentum on December 16, 2024
| On December 17 2024 Edgewise Therapeutics was traded for 30.17 at the closing time. The top price for the day was 33.38 and the lowest listed price was 29.97 . The trading volume for the day was 1.6 M. The trading history from December 17, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 7.71% . The overall trading delta against the current closing price is 6.58% . |
Edgewise Therapeutics Fundamentals Correlations and Trends
By evaluating Edgewise Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Edgewise financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Edgewise Therapeutics Stock history
Edgewise Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Edgewise is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Edgewise Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Edgewise Therapeutics stock prices may prove useful in developing a viable investing in Edgewise Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 63.7 M | 58.4 M | |
| Net Loss | -60.9 M | -57.8 M |
Edgewise Therapeutics Quarterly Net Working Capital |
|
Edgewise Therapeutics Stock Technical Analysis
Edgewise Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Edgewise Therapeutics Period Price Range
Low | December 20, 2024
| High |
0.00 | 0.00 |
Edgewise Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Edgewise Therapeutics December 20, 2024 Market Strength
Market strength indicators help investors to evaluate how Edgewise Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Edgewise Therapeutics shares will generate the highest return on investment. By undertsting and applying Edgewise Therapeutics stock market strength indicators, traders can identify Edgewise Therapeutics entry and exit signals to maximize returns
Edgewise Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Edgewise Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Edgewise Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Edgewise to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1122 | |||
| Jensen Alpha | 0.967 | |||
| Total Risk Alpha | 0.7687 | |||
| Sortino Ratio | 0.2807 | |||
| Treynor Ratio | 0.7676 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.